Charles Zhu
Stock Analyst at LifeSci Capital
(2.76)
# 1,855
Out of 4,883 analysts
25
Total ratings
54.55%
Success rate
20.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CBIO Crescent Biopharma | Initiates: Outperform | $22 | $15.30 | +43.79% | 1 | Jun 18, 2025 | |
RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.42 | - | 1 | Dec 13, 2024 | |
TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $5.43 | +47.33% | 3 | Nov 7, 2024 | |
MGNX MacroGenics | Upgrades: Buy | $12 | $1.36 | +782.35% | 4 | Nov 7, 2023 | |
MRUS Merus | Maintains: Buy | $46 → $48 | $52.52 | -8.61% | 6 | Aug 8, 2023 | |
NUVL Nuvalent | Initiates: Buy | $56 | $77.92 | -28.13% | 1 | Jul 24, 2023 | |
TARA Protara Therapeutics | Assumes: Buy | $22 | $2.82 | +681.53% | 1 | Jul 10, 2023 | |
COGT Cogent Biosciences | Reiterates: Buy | $26 | $9.35 | +178.07% | 3 | Jun 13, 2023 | |
IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $21.17 | +51.16% | 3 | Mar 8, 2023 | |
ZYME Zymeworks | Upgrades: Buy | $14 | $13.08 | +7.03% | 2 | May 5, 2022 |
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $15.30
Upside: +43.79%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.42
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $5.43
Upside: +47.33%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.36
Upside: +782.35%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $52.52
Upside: -8.61%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $77.92
Upside: -28.13%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $2.82
Upside: +681.53%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $9.35
Upside: +178.07%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $21.17
Upside: +51.16%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $13.08
Upside: +7.03%